Peter Tippett

Last updated
Peter Tippett
Peter S. Tippett, MD, PhD.jpg
Born
Peter S. Tippett

1953 (age 70–71)
Dearborn, Michigan, U.S.
NationalityAmerican
Education Kalamazoo College, B.A., Biology (1975); Rockefeller University, Research Assistant to Nobel Prize winner Robert Bruce Merrifield (1975-1976); Case Western Reserve University, Ph.D. in Biochemistry (1981); Case Western Reserve University, Doctor of Medicine (1983); American Board of Internal Medicine, Diplomate Certified, Internal Medicine (1987)
Medical career
Profession Medicine
Field Internal Medicine
Institutions Case Western Reserve University Department of Biochemistry; The Pacific Foundation for the Advancement of Science and Medicine; Cleveland Metropolitan General Hospital; Euclid Hospital; Daniel Freeman Marina Hospital
Sub-specialties Biochemistry
ResearchSolid Phase Peptide Synthesis of Immunoglobulin Hypervariable Regions; Synthesis of Smallest Active Complement Peptides from C3 and C5; Hepatic Glucokinase -- Kinetics, Regulation, and Turnover; Palmitoyl CoA's Role as a Metabolic Effector; Protein-lipid Interactions; Measurement of Critical Micelle Concentrations; Hypomagnesemia, Meperidine Related Seizures in Renal Failure; Cardiologic Effect of Heat Stroke.

Peter S. Tippett (born 1953) is an American physician, researcher, and inventor known for contributions to information security, clinical medicine, and technology. These contributions include the development of the anti-virus program "Corporate Vaccine". [1] Tippett was Vice President of Verizon's Innovations Incubator and Chief Medical Officer for Verizon Enterprise Services from 2009 to 2015. He is currently the Founder and CEO of careMESH Inc. [2]

Contents

Early life and education

Born in 1953 and raised in Dearborn, Michigan, Tippett is an alumnus of Kalamazoo College and holds both a Ph.D. and M.D. from Case Western Reserve University School of Medicine. He studied at the Rockefeller University in New York under Nobel Prize winner Robert Bruce Merrifield, directing his doctoral research efforts toward the metabolic indicators of peptide synthesis. He completed his internship and residency in Internal Medicine at Cleveland Metropolitan General Hospital, and spent 1975-1985 engaged in biochemical research.

Work history

While engaged in research at Case Western Reserve, Tippett moonlighted as an emergency room physician and instructor in Emergency and Outpatient Medicine and spent much of his early clinical career (1989-1995) in Emergency Medicine in Ohio and California. He received his board certification in Internal Medicine in 1987. Between 1993 and 2000, he served on the board of the Computer Ethics Institute. [3]

He served as executive director of The Pacific Foundation for Science and Medicine from 1988 to 1992, an intersection of his clinical career with an emerging focus on technology, particularly in the arena of cybersecurity as well as the use and access protocols of the Internet. It was in his role as president and chairman of Certus International, a publisher and developer of PC anti-virus and security software, that Tippett applied his research insights as a biochemist to the concept of computer "viruses" to develop the anti-virus software, "Vaccine," which was later purchased by Symantec in 1992. [4] His CEO role with Cybertrust led to a merger of Cybertrust by Verizon and to Tippett's role in the Verizon healthcare and security innovations divisions. Tippett served as chairman of the Alliance for Internet Security in 2000. [5] He represented Verizon on the board of directors of The Open Identity Exchange (OIX) [6] and the Information Card Foundation. [7]

Technological achievements

In addition to being credited with the development of one of the first anti-virus programs, "Vaccine", Tippett pioneered and commercialized a string of now-common technologies including what is now called the "Recovery Disk," processor image signatures, using hash-tables for trusted file execution and anomaly detection, aspects of mail merge and "un-do." [1] He ran a bulletin board system for CP/M software before the first IBM PC was created and was president of the Cleveland Osborne Group (a user group for the computers of the Osborne Computer Corporation) in the early 1980s.

As chief scientist for ICSA.net, Tippett was one of a handful of experts to identify and address [8] the ILOVEYOU virus that broke in May 2000 [9] and provided key information to the Department of Justice about David Smith, the writer of the Melissa virus. [10] He was featured and on the cover of the August 2000 issue of Time Digital magazine. [11]

Professional activities

Tippett's work in the cybersecurity space has led to roles as speaker, contributor and advisor to government and private sector organizations. From 2003-2005, [12] he served on the President's Information Technology Committee (PITAC), established by Congress in 1997 under the High Performance Computing Act of 1991 to "guide the Administration's efforts to accelerate the development and adoption of information technologies vital for American prosperity in the 21st century." [13]

The U.S. Chamber of Commerce awarded Tippett its first Leadership in Health Care Award at the Chamber’s first annual Health Care Summit (2012) for his leadership of Verizon's incubator. [14] Tippett was also Chief Scientist for ICSA Labs and previously served as president of the International Computer Security Association. [15]

Tippett is currently an Adjunct Professor, Division of General Medical Sciences at Case Western Reserve University School of Medicine. [16]

In November 2017, T.E.N., a technology and information security executive networking and relationship-marketing firm, announced that Tippett was the recipient of the 2017 ISE® Luminary Leadership Award. [17]

Clinical publications

Related Research Articles

<span class="mw-page-title-main">Antigen</span> Molecule triggering an immune response (antibody production) in the host

In immunology, an antigen (Ag) is a molecule, moiety, foreign particulate matter, or an allergen, such as pollen, that can bind to a specific antibody or T-cell receptor. The presence of antigens in the body may trigger an immune response.

<span class="mw-page-title-main">Antiviral drug</span> Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are a class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.

A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

<span class="mw-page-title-main">Albert Sabin</span> Medical researcher

Albert Bruce Sabin was a Polish-American medical researcher, best known for developing the oral polio vaccine, which has played a key role in nearly eradicating the disease. In 1969–72, he served as the president of the Weizmann Institute of Science in Israel.

<span class="mw-page-title-main">Epitope mapping</span> Identifying the binding site of an antibody on its target antigen

In immunology, epitope mapping is the process of experimentally identifying the binding site, or epitope, of an antibody on its target antigen. Identification and characterization of antibody binding sites aid in the discovery and development of new therapeutics, vaccines, and diagnostics. Epitope characterization can also help elucidate the binding mechanism of an antibody and can strengthen intellectual property (patent) protection. Experimental epitope mapping data can be incorporated into robust algorithms to facilitate in silico prediction of B-cell epitopes based on sequence and/or structural data.

In academia, computational immunology is a field of science that encompasses high-throughput genomic and bioinformatics approaches to immunology. The field's main aim is to convert immunological data into computational problems, solve these problems using mathematical and computational approaches and then convert these results into immunologically meaningful interpretations.

A mimotope is often a peptide, and mimics the structure of an epitope. Because of this property it causes an antibody response similar to the one elicited by the epitope. An antibody for a given epitope antigen will recognize a mimotope which mimics that epitope. Mimotopes are commonly obtained from phage display libraries through biopanning. Vaccines utilizing mimotopes are being developed. Mimotopes are a kind of peptide aptamers.

<span class="mw-page-title-main">MAPK3</span> Protein-coding gene in the species Homo sapiens

Mitogen-activated protein kinase 3, also known as p44MAPK and ERK1, is an enzyme that in humans is encoded by the MAPK3 gene.

<span class="mw-page-title-main">Peptide transporter 1</span> Mammalian protein found in Homo sapiens

Peptide transporter 1 also known as solute carrier family 15 member 1 (SLC15A1) is a protein that in humans is encoded by SLC15A1 gene. PepT 1 is a solute carrier for oligopeptides. It functions in renal oligopeptide reabsorption and in the intestines in a proton dependent way, hence acting like a cotransporter.

<span class="mw-page-title-main">NFYB</span> Protein-coding gene in the species Homo sapiens

Nuclear transcription factor Y subunit beta is a protein that in humans is encoded by the NFYB gene.

<span class="mw-page-title-main">Pyroglutamylated RFamide peptide receptor</span> Protein-coding gene in the species Homo sapiens

Pyroglutamylated RFamide peptide receptor also known as orexigenic neuropeptide QRFP receptor or G-protein coupled receptor 103 (GPR103) is a protein that in humans is encoded by the QRFPR gene.

<span class="mw-page-title-main">Neuromedin U receptor 2</span> Protein-coding gene in the species Homo sapiens

Neuromedin-U receptor 2 is a protein that in humans is encoded by the NMUR2 gene.

<span class="mw-page-title-main">SOAT2</span> Protein-coding gene in the species Homo sapiens

Sterol O-acyltransferase 2, also known as SOAT2, is an enzyme that in humans is encoded by the SOAT2 gene.

<span class="mw-page-title-main">GSPT2</span> Protein-coding gene in humans

Eukaryotic peptide chain release factor GTP-binding subunit ERF3B is an enzyme that in humans is encoded by the GSPT2 gene.

<span class="mw-page-title-main">SLC27A6</span> Protein-coding gene in the species Homo sapiens

Long-chain fatty acid transport protein 6 is a protein that in humans is encoded by the SLC27A6 gene.

A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

Software for COVID-19 pandemic mitigation takes many forms. It includes mobile apps for contact tracing and notifications about infection risks, vaccine passports, software for enabling – or improving the effectiveness of – lockdowns and social distancing, Web software for the creation of related information services, and research and development software. A common issue is that few apps interoperate, reducing their effectiveness.

<span class="mw-page-title-main">Ramakanth Sarabu</span> Indian chemist (1955–2021)

Ramakanth Sarabu was an Indian organic chemist. He is known for his contributions in diabetes research, specifically the work of Glucokinase activation as a treatment therapy for type 2 diabetes.

References

  1. 1 2 "PC Mag". 1989-04-25.
  2. ↑ "careMESH". careMESH. Retrieved 2020-04-23.
  3. ↑ "Computer Ethics Institute". Archived from the original on 2013-12-13. Retrieved 2013-12-10.
  4. ↑ "Cybertrust". 2005-08-30. Archived from the original on 2005-08-30. Retrieved 2020-04-23.
  5. ↑ http://www.thefreelibrary.com/650-Member+Alliance+for+Internet+Security+Unveils+Tool+to+Detect...-a060577625 [ dead link ]
  6. ↑ "Board of Directors | Open Identity Exchange". Archived from the original on 2013-11-10. Retrieved 2013-12-10.
  7. ↑ "BOARD OF DIRECTORS". Archived from the original on 2016-01-22.
  8. ↑ Grossman, Lev (2000-05-15). "Attack of the Love Bug". Time. ISSN   0040-781X . Retrieved 2020-04-23.
  9. ↑ Max, Kevin (4 May 2000). "I Love You, I Kill You: Amorous Virus Invades the Email World". TheStreet. Retrieved 2020-04-23.
  10. ↑ Smothers, Ronald (1999-12-10). "Man Pleads Guilty to Creating Melissa Virus". The New York Times. ISSN   0362-4331 . Retrieved 2020-04-23.
  11. ↑ Time (magazine) [ dead link ]
  12. ↑ "The Networking and Information Technology Research and Development (NITRD) Program". www.nitrd.gov. Retrieved 2020-04-23.
  13. ↑ "Historical Documents". www.nitrd.gov. Retrieved 2020-04-23.
  14. ↑ http://www.emrandehrnew.com/2012/11/04/verizons-dr-peter-tippett-receives-u-s-chambers-first-leadership-in-health-care-award/%5B%5D
  15. ↑ "Information Systems Security Association". ISSA International. Retrieved 2020-04-23.
  16. ↑ "School of Medicine Faculty < Case Western Reserve University". bulletin.case.edu. Retrieved 2020-04-23.
  17. ↑ "ISE Awards". ten-inc.com. Retrieved 2020-04-23.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.